CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
Tranexamic aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05359172
NCT05359172N/ACompleted

Does Tranexamic Acid Significantly Reduce Total Blood Loss During Proximal Femoral Nailing for the Intertrochanteric Femoral Fracture in the Elderly?

Haseki Training and Research Hospital·observational·Posted May 3, 2022·Updated Oct 10, 2022

In Brief

An observational study evaluating Tranexamic acid for Hip Fractures and 2 related conditions. Completed, enrolled 100 participants across 1 site.

Detailed Summary

Blood loss is an important issue following intertrochanteric femoral fracture and may lead to requiring blood transfusions and transfusion complications. Tranexamic acid is a commonly used drug to decrease blood loss and the number of transfusions. The aim of our study is to determine the effectiveness of tranexamic acid use to reduce total blood loss during proximal femoral nailing for the intertrochanteric femoral fracture in the elderly. Patients aged \>65 years and diagnosed with intertrochanteric fracture will be included in the study. The patients will be numbered according to the admission to the hospital and randomly divided into two groups. First group will receive tranexamic acid infusion and second group will not receive tranexamic acid infusion. Total blood loss will be calculated using Nadler formula. The primary outcome of the study is total blood loss. The secondary outcomes are a number of transfusions, and surgical blood loss during the operative procedure.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMay 3, 2022
Enrollment StartApr 1, 2021
Primary CompletionJul 9, 2022
Study CompletionJul 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.2 years ago

Interventions

Tranexamic aciddrug

preoperative intravenous infusion